Opexa FY09 Net Loss Narrows
The company has reported a net loss of $1,433,922, or ($0.11) per share, compared with a net loss of $11,852,152, or ($1.12) per share. Opexa has posted an
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).